High-dose vitamin D3 to improve outcomes in the convalescent phase of complicated severe acute malnutrition in Pakistan: a double-blind randomised controlled trial (ViDiSAM)

Abstract We have previously shown that high-dose vitamin D3 improved weight gain and neurodevelopmental indices in children receiving standard therapy for uncomplicated severe acute malnutrition (SAM). Here we present results of a randomised placebo-controlled trial in Lahore, Pakistan, to determine...

Full description

Saved in:
Bibliographic Details
Main Authors: Javeria Saleem, Rubeena Zakar, Muhammad Salman Butt, Rameeza Kaleem, Asif Chaudhary, Jaya Chandna, David A. Jolliffe, Joseph Piper, Zaigham Abbas, Jonathan C. Y. Tang, William D. Fraser, Nick Freemantle, Andrew J. Prendergast, Adrian R. Martineau
Format: Article
Language:English
Published: Nature Portfolio 2025-03-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-57803-9
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849773846910992384
author Javeria Saleem
Rubeena Zakar
Muhammad Salman Butt
Rameeza Kaleem
Asif Chaudhary
Jaya Chandna
David A. Jolliffe
Joseph Piper
Zaigham Abbas
Jonathan C. Y. Tang
William D. Fraser
Nick Freemantle
Andrew J. Prendergast
Adrian R. Martineau
author_facet Javeria Saleem
Rubeena Zakar
Muhammad Salman Butt
Rameeza Kaleem
Asif Chaudhary
Jaya Chandna
David A. Jolliffe
Joseph Piper
Zaigham Abbas
Jonathan C. Y. Tang
William D. Fraser
Nick Freemantle
Andrew J. Prendergast
Adrian R. Martineau
author_sort Javeria Saleem
collection DOAJ
description Abstract We have previously shown that high-dose vitamin D3 improved weight gain and neurodevelopmental indices in children receiving standard therapy for uncomplicated severe acute malnutrition (SAM). Here we present results of a randomised placebo-controlled trial in Lahore, Pakistan, to determine whether two oral doses of 200,000 international units (IU) vitamin D3 (the first administered on or before the day of hospital discharge and the second administered 14 days later) would benefit children aged 6-59 months during the convalescent phase of complicated SAM. Eligible participants were individually randomised to intervention vs. control arms with a one-to-one allocation ratio and stratification by hospital of recruitment using computer-generated random sequences. Double-blinding to treatment allocation was maintained by concealing allocation from participants’ parents or guardians, their medical care providers, and all trial staff. The primary outcome was mean weight-for-height or -length z-score (WHZ) at 2-month follow-up. Secondary efficacy outcomes included mean WHZ at 6-month follow-up and mean lean mass index, Malawi Development Assessment Tool (MDAT) scores and serum 25-hydroxyvitamin D (25[OH]D) concentrations at 2- and 6-month follow-up. The trial has now completed. 259 children were randomised (128 to vitamin D, 131 to placebo), of whom 251 (96.9%) contributed data to analysis of the primary outcome (123 allocated to vitamin D, 128 to placebo). At 2-month follow-up, participants allocated to vitamin D had significantly higher mean serum 25(OH)D concentrations than those allocated to placebo (adjusted mean difference [aMD] 100.0 nmol/L, 95% confidence interval [CI] 72.2–127.8 nmol/L). This was not associated with an inter-arm difference in mean WHZ at 2-month follow-up (aMD 0.02, 95% CI −0.20 to 0.23), or in any anthropometric or neurodevelopmental secondary outcome assessed at 2- or 6-month follow-up. The intervention was safe. In conclusion, high-dose vitamin D3 elevated mean serum 25(OH)D concentrations in children receiving standard therapy for complicated SAM in Pakistan, but did not influence any anthropometric or neurodevelopmental outcome studied. The trial was registered at ClinicalTrials.gov with the identifier NCT04270643.
format Article
id doaj-art-a1bf70b638034eb29ae25c485fb3cb74
institution DOAJ
issn 2041-1723
language English
publishDate 2025-03-01
publisher Nature Portfolio
record_format Article
series Nature Communications
spelling doaj-art-a1bf70b638034eb29ae25c485fb3cb742025-08-20T03:01:55ZengNature PortfolioNature Communications2041-17232025-03-0116111210.1038/s41467-025-57803-9High-dose vitamin D3 to improve outcomes in the convalescent phase of complicated severe acute malnutrition in Pakistan: a double-blind randomised controlled trial (ViDiSAM)Javeria Saleem0Rubeena Zakar1Muhammad Salman Butt2Rameeza Kaleem3Asif Chaudhary4Jaya Chandna5David A. Jolliffe6Joseph Piper7Zaigham Abbas8Jonathan C. Y. Tang9William D. Fraser10Nick Freemantle11Andrew J. Prendergast12Adrian R. Martineau13Department of Public Health, University of the PunjabDepartment of Public Health, University of the PunjabDepartment of Public Health, University of the PunjabSir Ganga Ram HospitalTHQ HospitalDepartment of Infectious Disease Epidemiology and International Health, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical MedicineBlizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of LondonBlizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of LondonInstitute of Microbiology and Molecular Genetics, University of the PunjabNorwich Medical School, University of East AngliaNorwich Medical School, University of East AngliaComprehensive Clinical Trials Unit, University College LondonBlizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of LondonBlizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of LondonAbstract We have previously shown that high-dose vitamin D3 improved weight gain and neurodevelopmental indices in children receiving standard therapy for uncomplicated severe acute malnutrition (SAM). Here we present results of a randomised placebo-controlled trial in Lahore, Pakistan, to determine whether two oral doses of 200,000 international units (IU) vitamin D3 (the first administered on or before the day of hospital discharge and the second administered 14 days later) would benefit children aged 6-59 months during the convalescent phase of complicated SAM. Eligible participants were individually randomised to intervention vs. control arms with a one-to-one allocation ratio and stratification by hospital of recruitment using computer-generated random sequences. Double-blinding to treatment allocation was maintained by concealing allocation from participants’ parents or guardians, their medical care providers, and all trial staff. The primary outcome was mean weight-for-height or -length z-score (WHZ) at 2-month follow-up. Secondary efficacy outcomes included mean WHZ at 6-month follow-up and mean lean mass index, Malawi Development Assessment Tool (MDAT) scores and serum 25-hydroxyvitamin D (25[OH]D) concentrations at 2- and 6-month follow-up. The trial has now completed. 259 children were randomised (128 to vitamin D, 131 to placebo), of whom 251 (96.9%) contributed data to analysis of the primary outcome (123 allocated to vitamin D, 128 to placebo). At 2-month follow-up, participants allocated to vitamin D had significantly higher mean serum 25(OH)D concentrations than those allocated to placebo (adjusted mean difference [aMD] 100.0 nmol/L, 95% confidence interval [CI] 72.2–127.8 nmol/L). This was not associated with an inter-arm difference in mean WHZ at 2-month follow-up (aMD 0.02, 95% CI −0.20 to 0.23), or in any anthropometric or neurodevelopmental secondary outcome assessed at 2- or 6-month follow-up. The intervention was safe. In conclusion, high-dose vitamin D3 elevated mean serum 25(OH)D concentrations in children receiving standard therapy for complicated SAM in Pakistan, but did not influence any anthropometric or neurodevelopmental outcome studied. The trial was registered at ClinicalTrials.gov with the identifier NCT04270643.https://doi.org/10.1038/s41467-025-57803-9
spellingShingle Javeria Saleem
Rubeena Zakar
Muhammad Salman Butt
Rameeza Kaleem
Asif Chaudhary
Jaya Chandna
David A. Jolliffe
Joseph Piper
Zaigham Abbas
Jonathan C. Y. Tang
William D. Fraser
Nick Freemantle
Andrew J. Prendergast
Adrian R. Martineau
High-dose vitamin D3 to improve outcomes in the convalescent phase of complicated severe acute malnutrition in Pakistan: a double-blind randomised controlled trial (ViDiSAM)
Nature Communications
title High-dose vitamin D3 to improve outcomes in the convalescent phase of complicated severe acute malnutrition in Pakistan: a double-blind randomised controlled trial (ViDiSAM)
title_full High-dose vitamin D3 to improve outcomes in the convalescent phase of complicated severe acute malnutrition in Pakistan: a double-blind randomised controlled trial (ViDiSAM)
title_fullStr High-dose vitamin D3 to improve outcomes in the convalescent phase of complicated severe acute malnutrition in Pakistan: a double-blind randomised controlled trial (ViDiSAM)
title_full_unstemmed High-dose vitamin D3 to improve outcomes in the convalescent phase of complicated severe acute malnutrition in Pakistan: a double-blind randomised controlled trial (ViDiSAM)
title_short High-dose vitamin D3 to improve outcomes in the convalescent phase of complicated severe acute malnutrition in Pakistan: a double-blind randomised controlled trial (ViDiSAM)
title_sort high dose vitamin d3 to improve outcomes in the convalescent phase of complicated severe acute malnutrition in pakistan a double blind randomised controlled trial vidisam
url https://doi.org/10.1038/s41467-025-57803-9
work_keys_str_mv AT javeriasaleem highdosevitamind3toimproveoutcomesintheconvalescentphaseofcomplicatedsevereacutemalnutritioninpakistanadoubleblindrandomisedcontrolledtrialvidisam
AT rubeenazakar highdosevitamind3toimproveoutcomesintheconvalescentphaseofcomplicatedsevereacutemalnutritioninpakistanadoubleblindrandomisedcontrolledtrialvidisam
AT muhammadsalmanbutt highdosevitamind3toimproveoutcomesintheconvalescentphaseofcomplicatedsevereacutemalnutritioninpakistanadoubleblindrandomisedcontrolledtrialvidisam
AT rameezakaleem highdosevitamind3toimproveoutcomesintheconvalescentphaseofcomplicatedsevereacutemalnutritioninpakistanadoubleblindrandomisedcontrolledtrialvidisam
AT asifchaudhary highdosevitamind3toimproveoutcomesintheconvalescentphaseofcomplicatedsevereacutemalnutritioninpakistanadoubleblindrandomisedcontrolledtrialvidisam
AT jayachandna highdosevitamind3toimproveoutcomesintheconvalescentphaseofcomplicatedsevereacutemalnutritioninpakistanadoubleblindrandomisedcontrolledtrialvidisam
AT davidajolliffe highdosevitamind3toimproveoutcomesintheconvalescentphaseofcomplicatedsevereacutemalnutritioninpakistanadoubleblindrandomisedcontrolledtrialvidisam
AT josephpiper highdosevitamind3toimproveoutcomesintheconvalescentphaseofcomplicatedsevereacutemalnutritioninpakistanadoubleblindrandomisedcontrolledtrialvidisam
AT zaighamabbas highdosevitamind3toimproveoutcomesintheconvalescentphaseofcomplicatedsevereacutemalnutritioninpakistanadoubleblindrandomisedcontrolledtrialvidisam
AT jonathancytang highdosevitamind3toimproveoutcomesintheconvalescentphaseofcomplicatedsevereacutemalnutritioninpakistanadoubleblindrandomisedcontrolledtrialvidisam
AT williamdfraser highdosevitamind3toimproveoutcomesintheconvalescentphaseofcomplicatedsevereacutemalnutritioninpakistanadoubleblindrandomisedcontrolledtrialvidisam
AT nickfreemantle highdosevitamind3toimproveoutcomesintheconvalescentphaseofcomplicatedsevereacutemalnutritioninpakistanadoubleblindrandomisedcontrolledtrialvidisam
AT andrewjprendergast highdosevitamind3toimproveoutcomesintheconvalescentphaseofcomplicatedsevereacutemalnutritioninpakistanadoubleblindrandomisedcontrolledtrialvidisam
AT adrianrmartineau highdosevitamind3toimproveoutcomesintheconvalescentphaseofcomplicatedsevereacutemalnutritioninpakistanadoubleblindrandomisedcontrolledtrialvidisam